| LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy M Pascual-García, E Bonfill-Teixidor, E Planas-Rigol, C Rubio-Perez, ... Nature communications 10 (1), 2416, 2019 | 169 | 2019 |
| Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid F Martínez-Ricarte, R Mayor, E Martínez-Sáez, C Rubio-Pérez, E Pineda, ... Clinical Cancer Research 24 (12), 2812-2819, 2018 | 159 | 2018 |
| Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment L Muinelo-Romay, M Vieito, A Abalo, M Alonso Nocelo, F Barón, U Anido, ... Cancers 6 (1), 153-165, 2014 | 123 | 2014 |
| Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer L Alonso-Alconada, L Muinelo-Romay, K Madissoo, A Diaz-Lopez, ... Molecular cancer 13, 1-10, 2014 | 113 | 2014 |
| Molecular characterization of circulating tumor cells in human metastatic colorectal cancer J Barbazan, L Alonso-Alconada, L Muinelo-Romay, M Vieito, A Abalo, ... PloS one 7 (7), e40476, 2012 | 111 | 2012 |
| Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria I Matos, J Martin-Liberal, A García-Ruiz, C Hierro, M Ochoa de Olza, ... Clinical Cancer Research 26 (8), 1846-1855, 2020 | 87 | 2020 |
| A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer J Barbazan, L Muinelo‐Romay, M Vieito, S Candamio, A Díaz‐López, ... International journal of cancer 135 (11), 2633-2643, 2014 | 77 | 2014 |
| Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma V Moreno, JM Sepulveda, M Vieito, T Hernández-Guerrero, B Doger, ... Annals of Oncology 31 (6), 780-788, 2020 | 48 | 2020 |
| Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. I Matos, J Martin-Liberal, C Hierro, M Ochoa De Olza, C Viaplana, ... Journal of Clinical Oncology 36 (15_suppl), 3032-3032, 2018 | 46 | 2018 |
| Effectiveness of prone positioning in nonintubated intensive care unit patients with moderate to severe acute respiratory distress syndrome by coronavirus disease 2019 M Taboada, M Gonzalez, A Alvarez, I Gonzalez, J Garcia, M Eiras, ... Anesthesia & Analgesia 132 (1), 25-30, 2021 | 37 | 2021 |
| A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer J Barbazán, M Vieito, A Abalo, L Alonso‐Alconada, L Muinelo‐Romay, ... Journal of cellular and molecular medicine 16 (10), 2342-2349, 2012 | 32 | 2012 |
| Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial MI de la Fuente, H Colman, M Rosenthal, BA Van Tine, D Levacic, ... Neuro-oncology 25 (1), 146-156, 2023 | 31 | 2023 |
| First-in-human phase I study of a next-generation, oral, TGFβ receptor 1 inhibitor, LY3200882, in patients with advanced cancer TA Yap, M Vieito, C Baldini, JM Sepúlveda-Sánchez, S Kondo, ... Clinical Cancer Research 27 (24), 6666-6676, 2021 | 31 | 2021 |
| Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic … A Gazzah, C Ricordel, S Cousin, BC Cho, E Calvo, TM Kim, C Helissey, ... Journal of Clinical Oncology 38 (15_suppl), 9505-9505, 2020 | 30 | 2020 |
| Association of breast cancer and obesity in a homogeneous population from Spain AB Crujeiras, J Cueva, M Vieito, T Curiel, R Lopez-Lopez, M Pollan, ... Journal of Endocrinological Investigation 35, 681-685, 2012 | 28 | 2012 |
| Molecular profiling of circulating tumour cells identifies Notch1 as a principal regulator in advanced non-small cell lung cancer J Mariscal, M Alonso-Nocelo, L Muinelo-Romay, J Barbazan, M Vieito, ... Scientific reports 6 (1), 37820, 2016 | 27 | 2016 |
| Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients L León-Mateos, H Casas, A Abalo, M Vieito, M Abreu, U Anido, ... Oncotarget 8 (33), 54708, 2017 | 26 | 2017 |
| A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine. MI De La Fuente, H Colman, M Rosenthal, BA Van Tine, D Levaci, ... Journal of clinical oncology 38 (15_suppl), 2505-2505, 2020 | 21 | 2020 |
| First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors EJ Davis, J Martin-Liberal, R Kristeleit, DC Cho, SP Blagden, D Berthold, ... Journal for Immunotherapy of Cancer 10 (10), 2022 | 20 | 2022 |
| Zoledronic acid as an antimetastatic agent for different human tumor cell lines L Muinelo-Romay, D Garcia, L Alonso-Alconada, M Vieito, M Carmona, ... Anticancer Research 33 (12), 5295-5300, 2013 | 16 | 2013 |
